Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma
- 17 May 2013
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 462 (6) , 665-671
Abstract
Galectin-1 (GAL-1) is frequently expressed in osteosarcomas. Although a valuable diagnostic marker to differentiate between chondroblastic osteosarcomas and conventional chondrosarcomas, it has not been tested in the Ewing sarcoma family of tumors (ESFTs). We studied by immunohistochemistry GAL-1 expression in 43 osteosarcomas, 23 chondrosarcomas, and 217 genetically confirmed ESFTs using a tissue microarray. GAL-1 was expressed in 78 % of osteosarcomas, 33 % of chondrosarcomas, and 8 % of ESFTs. Osteoblastic and small cell osteosarcoma subtypes expressed GAL-1 in a high percentage of cells when compared with the other histological subtypes, whereas two chondroblastic osteosarcomas were negative. GAL-1 was mainly expressed in high-grade chondrosarcomas (grade III). ESFTs were rarely positive (8 %), and this was not related to the histological subtype nor to the clinical outcome. Although GAL-1 expression distinguishes chondroblastic osteosarcomas from conventional chondrosarcomas and is usually negative in conventional chondrosarcomas, the final diagnosis needs to incorporate histopathology since some chondroblastic osteosarcomas fail to express GAL-1, while high-grade chondrosarcomas are GAL-1 positive. Since GAL-1 is frequently expressed in osteogenic tumors, including small cell osteosarcoma, but rarely positive in ESFTs, its expression seems a valuable tool for distinguishing between these lesions. GAL-1 immunoexpression is not indicative of prognosis in ESFT.Keywords
This publication has 23 references indexed in Scilit:
- Small cell osteosarcoma with Ewing sarcoma breakpoint region 1 gene rearrangement detected by interphase fluorescence in situ hybridizationAnnals of Diagnostic Pathology, 2013
- A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced DiseaseCancer Research, 2013
- Overexpression of galectin‐1 is associated with poor prognosis in human hepatocellular carcinoma following resectionJournal of Gastroenterology and Hepatology, 2012
- Small cell osteosarcoma of the mandible: Case report and review of its diagnostic aspectsJournal of Oral and Maxillofacial Pathology, 2011
- A novel EWSR1‐CREB3L1 fusion transcript in a case of small cell osteosarcomaGenes, Chromosomes and Cancer, 2011
- Galectin-1 is silenced by promoter hypermethylation and its re-expression induces apoptosis in human colorectal cancer cellsCancer Letters, 2011
- Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's Sarcoma Family of TumorsInternational Journal of Cancer, 2010
- Galectin-Expression an urologischen TumorenDer Urologe, 2010
- Histological heterogeneity of Ewing’s sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical supportVirchows Archiv, 2009
- Translocation (11;22) in small cell osteosarcomaCancer Genetics and Cytogenetics, 1990